Table 2.

Programmatic impact in terms of the worm burden reduced, prevalent case years averted, and heavy infection case years averted, when treating with and without ivermectin co-administration.

Treatment strategy	Worm years averted (per 100)	Prevalent case years averted (per 100)	Heavy infection case years averted — lower thresholda (per 100)	Heavy infection case years averted — higher thresholda (per 100)
Fitted (higher) transmission setting
Standalone albendazole
Annual targeted treatment	24,290	52	55	19
Biannual targeted treatment	35,733	158	78	22
Ivermectin co-administration
Annual targeted treatment	33,653	118	75	22
Biannual targeted treatment	40,981	390	84	23
Lower transmission setting
Standalone albendazole
Annual targeted treatment	8,995	218	12.888	0.512
Biannual targeted treatment	10,055	276	13.353	0.517
Ivermectin co-administration
Annual targeted treatment	10,005	275	13.355	0.517
Biannual targeted treatment	10,858	363	13.538	0.518

Results assume 75% treatment coverage of Pre-SAC and SAC. Two different transmission settings were explored; lower (R₀ = 1.25), and higher (R₀ = 1.75 — fitted). The analysis was performed with a ten year time horizon (comparing ten years of standalone treatment to ivermectin co-administration). Note that those under five years of age did not receive ivermectin and would only be treated with albendazole.

^aThe thresholds for heavy infection are presented in Table 1.